Lipid Changes Differ Within HIV Drug Classes
In a pooled analysis of clinical trials, tenofovir-based therapies and those containing efavirenz or ritonavir-boosted atazanavir, darunavir, or saquinavir had the most favorable effects on plasma lipids.
Welcome to Journal Watch. The content you requested requires sign in with a username and password.
Sign In
Sign Up
Print subscribers
Activate your free online account for full access to all site content and features.
Other visitors
Subscribe for full access to all site content and features. ($99/year)
Purchase a site pass for full access to all articles. ($19/7 days)
Or, simply register for free access to email alerts, site features, and article archives. (FREE)